- Home
- AIRI vs NCNA Comparison
AIRI vs NCNA Comparison
Compare AIRI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- NCNA
- Stock Information
- Founded
- AIRI 1979
- NCNA 1997
- Country
- AIRI United States
- NCNA United Kingdom
- Employees
- AIRI N/A
- NCNA N/A
- Industry
- AIRI Military/Government/Technical
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- NCNA Health Care
- Exchange
- AIRI Nasdaq
- NCNA Nasdaq
- Market Cap
- AIRI 13.4M
- NCNA 15.4M
- IPO Year
- AIRI N/A
- NCNA 2017
- Fundamental
- Price
- AIRI $3.33
- NCNA $4.47
- Analyst Decision
- AIRI
- NCNA Buy
- Analyst Count
- AIRI 0
- NCNA 2
- Target Price
- AIRI N/A
- NCNA $25.00
- AVG Volume (30 Days)
- AIRI 100.8K
- NCNA 187.0M
- Earning Date
- AIRI 08-18-2025
- NCNA 08-18-2025
- Dividend Yield
- AIRI N/A
- NCNA N/A
- EPS Growth
- AIRI N/A
- NCNA N/A
- EPS
- AIRI N/A
- NCNA N/A
- Revenue
- AIRI $53,182,000.00
- NCNA N/A
- Revenue This Year
- AIRI N/A
- NCNA N/A
- Revenue Next Year
- AIRI $4.99
- NCNA N/A
- P/E Ratio
- AIRI N/A
- NCNA N/A
- Revenue Growth
- AIRI 0.29
- NCNA N/A
- 52 Week Low
- AIRI $3.00
- NCNA $0.03
- 52 Week High
- AIRI $9.44
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- AIRI 42.87
- NCNA 30.91
- Support Level
- AIRI $3.32
- NCNA $7.06
- Resistance Level
- AIRI $3.45
- NCNA $10.00
- Average True Range (ATR)
- AIRI 0.09
- NCNA 1.44
- MACD
- AIRI -0.02
- NCNA 0.07
- Stochastic Oscillator
- AIRI 12.00
- NCNA 3.94
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.